Chronic infection with HCV is a major cause of liver-related death worldwide and can be treated with interferon α therapy. This Review focuses on pegylated interferons and will discuss the mechanisms of action, structure, and pharmacokinetics of two different pegylated interferons—PEG-IFN-α2a and PEG-IFN-α2b. Alessio Aghemo and colleagues analyze all available data on these two pegylated interferons and discuss and directly compare the efficacy and safety of these drugs.
- Alessio Aghemo
- Maria Grazia Rumi
- Massimo Colombo
